drugset / Trial / NCT02822105

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

NCT02822105 ↗

Phase 1 Completed 96 enrolled FluGen Inc
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose is of this study is to assess the safety and tolerability of three dose levels of H3N2 M2SR influenza vaccine versus placebo delivered intranasally to healthy adult subjects.

Timeline

Start
2016-06
Primary completion
2017-04
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Subject H3N2 M2SR monovalent influenza vaccine Vaccine — Intranasal

Indications